Treatment of Patients With Resistant Cancer/ Post Allogeneic Stem Cell Transplantation With Donor Lymphocytes Sensitized by Antigens Expressed by the Host
Interventional
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Introducing more effective graft vs leukemia and graft vs tumor effects with immune donor lymphocytes in patients relapsing following allogeneic bone marrow or blood stem cell transplantation
Shimon Slavin, MD
Principal Investigator
Hadassah Medical Organization
Israel: Israeli Health Ministry Pharmaceutical Administration
240801-HMO-CTIL
NCT00149032
August 2001
Name | Location |
---|